406 related articles for article (PubMed ID: 27844413)
1. Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications.
Morbelli S; Ferrarazzo G; Pomposelli E; Pupo F; Pesce G; Calamia I; Fiz F; Clapasson A; Bauckneht M; Minuto M; Sambuceti G; Giusti M; Bagnasco M
J Endocrinol Invest; 2017 Apr; 40(4):417-424. PubMed ID: 27844413
[TBL] [Abstract][Full Text] [Related]
2. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
Ozkan E; Aras G; Kucuk NO
Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
[TBL] [Abstract][Full Text] [Related]
3. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
[TBL] [Abstract][Full Text] [Related]
4. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
[TBL] [Abstract][Full Text] [Related]
6. Role of Thyroglobulin Doubling Time in Differentiated Thyroid Cancer and Its Relationship with Demographic-Histopathologic Risk Factors and
Araz M; Soydal Ç; Özkan E; Akkuş P; Nak D; Küçük NÖ; Kır KM
Cancer Biother Radiopharm; 2021 Jun; 36(5):425-432. PubMed ID: 32379488
[No Abstract] [Full Text] [Related]
7. The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody.
Liu Y
Nucl Med Commun; 2016 Jun; 37(6):577-82. PubMed ID: 26813991
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
9.
Liu J; Liu B; Yu Y; Chao F; Liu Y; Han X
Hell J Nucl Med; 2018; 21(1):24-27. PubMed ID: 29550843
[TBL] [Abstract][Full Text] [Related]
10. [Recovery test or immunoradiometric measurement of anti-thyroglobulin autoantibodies for interpretation of thyroglobulin determination in the follow-up of different thyroid carcinoma].
Zöphel K; Wunderlich G; Liepach U; Koch R; Bredow J; Franke WG
Nuklearmedizin; 2001 Oct; 40(5):155-63. PubMed ID: 11727628
[TBL] [Abstract][Full Text] [Related]
11. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT.
Seo JH; Lee SW; Ahn BC; Lee J
Clin Endocrinol (Oxf); 2010 Apr; 72(4):558-63. PubMed ID: 19744107
[TBL] [Abstract][Full Text] [Related]
12. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
Ozkan E; Soydal C; Araz M; Aras G; Ibis E
Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.
Giovanella L; Ceriani L; De Palma D; Suriano S; Castellani M; Verburg FA
Head Neck; 2012 May; 34(5):626-31. PubMed ID: 21850699
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
[TBL] [Abstract][Full Text] [Related]
16. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
[TBL] [Abstract][Full Text] [Related]
17. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
[TBL] [Abstract][Full Text] [Related]
18. The Diagnostic Value of
Bang JI; Park S; Kim K; Seo Y; Chong A; Hong CM; Choi M; Lee SW; Oh SW
Thyroid; 2023 Oct; 33(10):1224-1236. PubMed ID: 37597200
[No Abstract] [Full Text] [Related]
19. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
